Home > Maligne hematologie > Lymfoïde ziekten > Non-Hodgkin lymfomen (NHL) > High-Grade B-Cell Lymphoma (HGBCL) > ZUMA23

ZUMA23

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 21-4-2024, 23:38